Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

2.040 +0.050 (+2.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention
By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology... 
Via Benzinga
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! 
Via InvestorPlace
Where Mainz Biomed Stands With Analysts
 
Via Benzinga
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
From Mainz BioMed NV
Via GlobeNewswire
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
--News Direct-- 
Via News Direct
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
The WHO reports that colorectal cancer is the second most fatal cancer around the world. 
Via Benzinga
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
From Mainz BioMed NV
Via GlobeNewswire
Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible
--News Direct-- 
Via News Direct
Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech
Colorectal cancer is the third most common cancer worldwide, and although the majority of colorectal cancer cases have historically occurred in individuals aged 45 and older, it is increasingly... 
Via Benzinga
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland 
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why US Steel Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue. 
Via Benzinga
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
Israel has one of the highest screening compliance rates in the world with over one million people being screened each year 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Secures up to $50M in New Funding
Provides option to access capital to support commercial and clinical programs 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Expands Commercial Footprint into Poland
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today 
Via PressReach
Topics Death
Being Overweight or Obese Increases Risk of Developing Colorectal Cancer
Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most... 
Via PressReach
Mainz Biomed Expands Commercial Footprint into Poland
From Mainz BioMed NV
Via GlobeNewswire
BioNTech’s mRNA Vaccine Shows Early Potential Against Pancreatic Cancer
One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system’s defense? One of the deadliest forms of cancer around,... 
Via PressReach
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
Colon Cancer Creeping Into Younger Adults – New R&D Uncovers Early Signs
Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are... 
Via PressReach
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.